NYSE:NUVBPharmaceuticals
Assessing Nuvation Bio (NUVB) Valuation After Safusidenib Moves Into Phase 3 Astrocytoma Trial
Nuvation Bio (NUVB) is back in focus after the company finalized a protocol amendment for its global SIGMA study, moving safusidenib into a Phase 3 trial for high-risk IDH1-mutant astrocytoma.
See our latest analysis for Nuvation Bio.
The protocol amendment appears to have kept attention on Nuvation Bio, with a 1-day share price return of 1.91% and a 7-day share price return of 2.98% at a latest share price of $5.88. The year-to-date share price return of a 31.47% decline contrasts with a...